-
1 Comment
Taiko Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 34.0% below its 200 day moving average.
From a valuation standpoint, the stock is 96.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Taiko Pharmaceutical Co.,Ltd's total revenue sank by 8.8% to $5B since the same quarter in the previous year.
Its net income has dropped by 33.5% to $988M since the same quarter in the previous year.
Based on the above factors, Taiko Pharmaceutical Co.,Ltd gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| CurrencyCode | JPY |
| ISIN | JP3442200006 |
| Exchange | TSE |
| PE Ratio | None |
|---|---|
| Target Price | 3300 |
| Market Cap | 14B |
| Beta | 0.33 |
| Dividend Yield | None |
Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines in Japan and internationally. The company provides OTC medicines for the treatment of loose stools, diarrhea, vomiting, food and water poisoning symptoms, and toothache; and quasi-drugs for regulation of intestinal movements, relieves stomach distention, loose stools, and constipation. It manufactures and sells infection control products. Taiko Pharmaceutical Co.,Ltd. exports its products. The company was incorporated in 1946 and is headquartered in Osaka, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4574.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
